Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995568 | 1.00 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19996150 | 0.81 | PDE4B (0.42) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19995887 | 0.81 | PDE4B (0.42) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19995563 | 0.78 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19995584 | 0.78 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19995974 | 0.72 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19995523 | 0.72 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL28298518 | 0.68 | QDPR (0.33) | — | |
| SCHEMBL20005713 | 0.67 | PDE4B (0.40) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19995527 | 0.67 | PDE4B (0.40) | RAB9ANPC1SMN1; SMN2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | RAB9A 943/4885NPC1 244/4885SMN1; SMN2 1617/4885 |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | RAB9A 970/4885NPC1 274/4885SMN1; SMN2 1758/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | RAB9A 967/4885NPC1 271/4885SMN1; SMN2 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.